Pazufloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pazufloxacin
Accession Number
DB11774
Type
Small Molecule
Groups
Investigational
Description

Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).

Structure
Thumb
Synonyms
Not Available
External IDs
T-3761
Product Ingredients
IngredientUNIICASInChI Key
Pazufloxacin Mesilate2XI226J1HS 163680-77-1UDHGFPATQWQARM-FJXQXJEOSA-N
Approved Prescription Products
Not Available
Approved Generic Prescription Products
Not Available
Approved Over the Counter Products
Not Available
Unapproved/Other Products
Not Available
International/Other Brands
Not Available
Brand mixtures
Not Available
Categories
UNII
4CZ1R38NDI
CAS number
127045-41-4
Weight
Average: 318.304
Monoisotopic: 318.101585134
Chemical Formula
C16H15FN2O4
InChI Key
XAGMUUZPGZWTRP-ZETCQYMHSA-N
InChI
InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1
IUPAC Name
(2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
SMILES
[H][[email protected]]1(C)COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C1(N)CC1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Pazufloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pazufloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Pazufloxacin.Experimental, Illicit
AcarbosePazufloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Pazufloxacin.Approved
AcenocoumarolPazufloxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pazufloxacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Pazufloxacin.Approved
AlbiglutidePazufloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Pazufloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Pazufloxacin.Experimental
AlogliptinPazufloxacin may increase the hypoglycemic activities of Alogliptin.Approved
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Pazufloxacin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Pazufloxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Pazufloxacin.Approved
AndrographolideHMPL-004 may increase the neuroexcitatory activities of Pazufloxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Pazufloxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Pazufloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Pazufloxacin.Approved
ApocyninAcetovanillone may increase the neuroexcitatory activities of Pazufloxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Pazufloxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Pazufloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pazufloxacin.Approved, Investigational
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Pazufloxacin.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Pazufloxacin.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BromfenacBromfenac may increase the neuroexcitatory activities of Pazufloxacin.Approved
BromocriptinePazufloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Pazufloxacin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pazufloxacin.Approved
CalciumCalcium can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Nutraceutical
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CarbonateCalcium carbonate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium citrate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CanagliflozinPazufloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the neuroexcitatory activities of Pazufloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
ChlorpropamidePazufloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
Choline magnesium trisalicylateTrisalicylate-choline may increase the neuroexcitatory activities of Pazufloxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Pazufloxacin.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Pazufloxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Pazufloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Pazufloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Pazufloxacin.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Pazufloxacin.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pazufloxacin.Approved, Investigational
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Pazufloxacin.Investigational
DapagliflozinPazufloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pazufloxacin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Pazufloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Pazufloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Pazufloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pazufloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Pazufloxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
DicoumarolPazufloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Pazufloxacin.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Pazufloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Pazufloxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Pazufloxacin.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Pazufloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pazufloxacin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Pazufloxacin.Approved
DisopyramidePazufloxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pazufloxacin.Approved, Investigational
DroxicamDroxicam may increase the neuroexcitatory activities of Pazufloxacin.Approved
DulaglutidePazufloxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Pazufloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Pazufloxacin.Approved
E-6201E6201 may increase the neuroexcitatory activities of Pazufloxacin.Investigational
EbselenEbselen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
EmpagliflozinPazufloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Pazufloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Pazufloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Pazufloxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Pazufloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Pazufloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
Ethyl biscoumacetatePazufloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Pazufloxacin.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Pazufloxacin.Approved
ExenatidePazufloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Pazufloxacin.Investigational
FenbufenFenbufen may increase the neuroexcitatory activities of Pazufloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved
Ferric CarboxymaltoseThe serum concentration of Pazufloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Pazufloxacin can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Pazufloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FloctafenineFloctafenine may increase the neuroexcitatory activities of Pazufloxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Pazufloxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pazufloxacin.Approved
FluindionePazufloxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Pazufloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Pazufloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Pazufloxacin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Pazufloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Pazufloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Pazufloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Pazufloxacin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Pazufloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Pazufloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Pazufloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pazufloxacin.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Pazufloxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Pazufloxacin.Approved, Investigational, Withdrawn
GliclazidePazufloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePazufloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePazufloxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburidePazufloxacin may increase the hypoglycemic activities of Glyburide.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Pazufloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pazufloxacin.Approved, Vet Approved
IbuprofenIbuprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Pazufloxacin.Approved
IndomethacinIndomethacin may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
Insulin AspartPazufloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirPazufloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlarginePazufloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisinePazufloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanPazufloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproPazufloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Pazufloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Pazufloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Pazufloxacin can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Pazufloxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Pazufloxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Pazufloxacin.Approved
LanreotidePazufloxacin may increase the hypoglycemic activities of Lanreotide.Approved
Lanthanum carbonateThe serum concentration of Pazufloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
LiraglutidePazufloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Pazufloxacin.Investigational
LornoxicamLornoxicam may increase the neuroexcitatory activities of Pazufloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium HydroxideMagnesium hydroxide can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateThe serum concentration of Pazufloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Pazufloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Pazufloxacin.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Pazufloxacin.Investigational
MecaserminPazufloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Pazufloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Pazufloxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Pazufloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Pazufloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
MetforminPazufloxacin may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pazufloxacin.Approved, Vet Approved
MifepristonePazufloxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolPazufloxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Pazufloxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pazufloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Pazufloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Pazufloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
NateglinidePazufloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Pazufloxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Pazufloxacin.Approved
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Pazufloxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Pazufloxacin.Approved, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
OctreotidePazufloxacin may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Pazufloxacin.Experimental
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Pazufloxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Pazufloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Pazufloxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Pazufloxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Pazufloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Pazufloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pazufloxacin.Approved, Vet Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Pazufloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Pazufloxacin.Approved
PasireotidePazufloxacin may increase the hypoglycemic activities of Pasireotide.Approved
PentamidinePazufloxacin may increase the hypoglycemic activities of Pentamidine.Approved
PhenindionePazufloxacin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonPazufloxacin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Pazufloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
PioglitazonePazufloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
PramlintidePazufloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Pazufloxacin.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Pazufloxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Pazufloxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pazufloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Pazufloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Pazufloxacin.Experimental
ProbenecidThe serum concentration of Pazufloxacin can be increased when it is combined with Probenecid.Approved
PropacetamolPropacetamol may increase the neuroexcitatory activities of Pazufloxacin.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Pazufloxacin.Investigational
QuinaprilThe serum concentration of Pazufloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuininePazufloxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinidePazufloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Pazufloxacin.Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Pazufloxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Pazufloxacin.Investigational, Withdrawn
RosiglitazonePazufloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Pazufloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Pazufloxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Pazufloxacin.Approved
SaxagliptinPazufloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SeratrodastSeratrodast may increase the neuroexcitatory activities of Pazufloxacin.Approved
SevelamerSevelamer can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SitagliptinPazufloxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SRT501SRT501 may increase the neuroexcitatory activities of Pazufloxacin.Investigational
Strontium ranelateThe serum concentration of Pazufloxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Pazufloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazinePazufloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazolePazufloxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Pazufloxacin.Approved
SulfisoxazolePazufloxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Pazufloxacin.Approved
SunitinibPazufloxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved, Withdrawn
TenoxicamTenoxicam may increase the neuroexcitatory activities of Pazufloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Pazufloxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Pazufloxacin.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Pazufloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Pazufloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Pazufloxacin.Approved
TolazamidePazufloxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamidePazufloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Pazufloxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Pazufloxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pazufloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Pazufloxacin.Approved, Vet Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Pazufloxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Pazufloxacin.Approved, Investigational
WarfarinPazufloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Pazufloxacin.Approved
ZileutonZileuton may increase the neuroexcitatory activities of Pazufloxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Pazufloxacin.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
ChemSpider
59360
ChEBI
94700
ChEMBL
CHEMBL240163
ATC Codes
J01MA18 — Pazufloxacin
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentOtitis Media (OM)1
2CompletedTreatmentConjunctivitis, Bacterial1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.41 mg/mLALOGPS
logP-0.51ALOGPS
logP-1ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)5.59ChemAxon
pKa (Strongest Basic)8.16ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.86 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity80.03 m3·mol-1ChemAxon
Polarizability30.76 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0296000000-cc353f5c3e0ddf62f272
Predicted LC-MS/MS Spectrum - 10V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 10V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, NegativePredicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / Hydroquinolones / Haloquinolines / Benzoxazines / Hydroquinolines / Pyridinecarboxylic acids / Alkyl aryl ethers / Aralkylamines / Aryl fluorides / Benzenoids
show 10 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / Dihydroquinolone / Haloquinoline / Dihydroquinoline / Benzoxazine / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Alkyl aryl ether / Aralkylamine
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Drug created on October 20, 2016 14:47 / Updated on September 01, 2017 12:13